LI-RADS超声监测2024版与2017版对比:肝细胞癌检出及可视化评分C的危险因素
该回顾性分析纳入407例肝硬化患者,比较LI-RADS超声监测2017版与2024版对肝细胞癌的检出效能,并分析随访监测中可视化评分C的预测因素。2024版较2017版敏感度更高但特异度更低,差异主要与甲胎蛋白升高而非仅升高有关;首次可视化评分C是后续可视化评分C的唯一独立预测因素。
要点
- 2024版较2017版敏感度提高(64.3% vs 42.9%/39.3%),特异度降低(82.1%/82.3% vs 92.6%/92.9%)。
- 2024版新增检出的7例肝细胞癌均伴甲胎蛋白升高,其中2例同时伴甲胎蛋白水平升高。
- 首次超声可视化评分C是后续可视化评分C的唯一独立预测因素(校正OR=21.04)。
核心结论
- 与2017版相比,LI-RADS超声监测2024版对肝细胞癌检出敏感度更高但特异度更低,主要与甲胎蛋白升高而非仅水平升高有关;后续超声可视化评分C的唯一独立预测因素是首次可视化评分C。
研究设计与样本
- 回顾性分析纳入407例肝硬化患者(男230例、女177例,中位年龄56岁),2011年11月至2014年8月作为前瞻性试验的一部分接受每半年一轮的监测超声;两名放射科医师独立对第1轮超声分类及第1、2轮可视化评分,第三名放射科医师仲裁分歧;肝细胞癌参考标准为活检阳性或MRI上LR-5观察。
诊断标准与关键数值
- 甲胎蛋白按2024版标准,较入组前水平升高或持续上升即视为阳性;肝细胞癌诊断参考标准为活检阳性或MRI上LR-5观察;2024版与2017版敏感度:读者1为64.3% vs 42.9%(p=.03),读者2为64.3% vs 39.3%(p=.02);特异度:读者1为82.1% vs 92.6%(p<.001),读者2为82.3% vs 92.9%(p<.001)。
临床应用与阅片要点
- 2024版较2017版敏感度更高但特异度更低,阅片时需结合甲胎蛋白动态变化(升高或持续上升)解读非阳性结果;首次超声可视化评分C提示后续监测仍易出现可视化评分C(校正OR=21.04,95%CI 10.84-40.83,p<.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The LI-RADS Ultrasound Surveillance algorithm was updated in 2024, incorporating α-fetoprotein (AFP) and a visualization score of VIS-C into management recommendations after nonpositive results. OBJECTIVE. The purpose of this study was to compare the diagnostic performance of LI-RADS Ultrasound Surveillance version 2017 (v2017) and version 2024 (v2024) for the detection of hepatocellular carcinoma (HCC) in at-risk patients and to identify predictors of VIS-C on follow-up surveillance examinations. METHODS. This retrospective analysis included 407 patients (230 men and 177 women; median age, 56 years) with cirrhosis who underwent rounds of semiannual surveillance ultrasound as part of a prospective trial from November 2011 to August 2014. Two radiologists independently assigned ultrasound categories to round 1 examinations and visualization scores to round 1 and round 2 examinations; a third radiologist adjudicated disagreements. The AFP level was considered positive if elevated or increasing from preenrollment values, per v2024 criteria. The reference standard for HCC was positive biopsy or an LR-5 observation on MRI. Diagnostic performance was compared between v2017 and v2024. Logistic regression analyses were performed to identify predictors of a round 2 VIS-C result, with attention given to risk factors for VIS-C described in v2024. RESULTS. HCC was diagnosed in 28 patients (6.9%). LI-RADS Ultrasound Surveillance v2024, in comparison with v2017, showed greater sensitivity for reader 1 (64.3% vs 42.9%, p = .03) and reader 2 (64.3% vs 39.3%, p = .02) and lower specificity for reader 1 (82.1% vs 92.6%, p < .001) and reader 2 (82.3% vs 92.9%, p < .001). All seven patients with HCC detected by v2024 but not v2017 by means of consensus assessments had increasing AFP; two also had elevated AFP. Among 299 patients who underwent round 2 ultrasound after negative round 1 v2024 surveillance results, the only independent predictor of a round 2 VIS-C result was a round 1 VIS-C result (adjusted OR = 21.04 [95% CI, 10.84-40.83], p < .001). For 88 of these patients with round 1 VIS-C, no v2024 risk factor showed a significant univariable association with repeat VIS-C. CONCLUSION. Compared with v2017, LI-RADS Ultrasound Surveillance v2024 had higher sensitivity but lower specificity for HCC detection, which was primarily related to increasing, rather than elevated, AFP. The only independent predictor of VIS-C on subsequent ultrasound was the initial VIS-C result. CLINICAL IMPACT. The findings support the use of LI-RADS Ultrasound Surveillance v2024 to improve HCC detection in at-risk patients.
引用
- Heo S, Kim SY, Lee SJ, et al. LI-RADS Ultrasound Surveillance Version 2024: Comparison With Version 2017 for Hepatocellular Carcinoma Detection and Risk Factors for Visualization Score C. AJR Am J Roentgenol. 2025. PMID: 39840963. doi:10.2214/AJR.24.32433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。